Yes, a TENS unit can help with arthritis pain, but modestly and mostly while it is switched on. In sham-controlled trials, active TENS has produced small-to-moderate improvements in knee osteoarthritis pain, with the largest effects reported during or immediately after a session. It is a low-risk adjunct rather than a disease-modifying treatment, and it does not slow joint damage. Expect help with comfort and function during activity, not a cure.
The question is worth taking seriously because arthritis pain is common, TENS devices are cheap and widely sold, and the marketing around them often outruns the evidence. This explainer separates the mechanism from the marketing. It covers what electrical stimulation actually does to nerves and joints, how large the measured effects are, who should avoid it, and how to test one without wasting money.
How electrical stimulation dampens joint pain signals
TENS delivers small electrical currents through skin electrodes to large sensory nerve fibers beneath the surface. The gate control theory, proposed in 1965, explains the basic trick. Signals from big, fast fibers carrying touch and vibration arrive at the spinal cord and activate inhibitory interneurons that suppress transmission from smaller, slower pain fibers. Rubbing a sore knee works on the same principle, which is why clinicians call it counterirritation. The device simply scales that effect up with a controllable current.
The deeper story involves the spinal cord's dorsal horn, where pain signals first synapse. Large-fiber activation releases gamma-aminobutyric acid and enkephalins, the body's own opioid peptides, which reduce the excitability of second-order neurons that would otherwise relay pain upward. This is why TENS analgesia builds over minutes rather than instantly, and why it fades soon after the electrodes come off. The gating is real but local and temporary.
A separate mechanism operates at higher frequencies. Conventional TENS, usually set between 80 and 120 Hz, produces rapid-onset, short-lasting relief suited to activity. Low-frequency TENS, around 2 to 4 Hz, and burst modes trigger slower, longer-lasting effects that appear to depend on endogenous opioid release, since naloxone can partially block them. This distinction matters practically: a session that feels ineffective at one setting may work at another.
What TENS does not do is alter cartilage, synovium, or joint mechanics. Osteoarthritis is a disease of tissue breakdown and joint loading; rheumatoid arthritis is an autoimmune inflammatory disease. Electrical stimulation reaches nerves, not the biology driving either condition. Any pain relief is symptomatic and occurs downstream of the joint itself. That single fact explains both the appeal and the ceiling of the device.
How large is the measured effect on arthritis pain?
The best evidence concerns knee osteoarthritis, the most studied joint. A 2020 network meta-analysis of randomized trials in knee osteoarthritis found that TENS produced small-to-moderate improvements in pain and function compared with sham stimulation, with effects measured on 100-point scales typically in the range of roughly 5 to 15 points. For context, the same review found exercise therapy outperforming most electrical modalities. A difference of 10 points on a 100-point pain scale sits near the threshold patients can actually feel, which tells you the effect is genuine but not dramatic.
The pattern across trials is consistent in one important way: effects are largest during stimulation and shrink or vanish at follow-up weeks after treatment stops. That time course separates TENS from interventions with carryover effects. It also explains why some reviews reach cautiously positive conclusions and others find no difference from sham. The disagreement often comes down to whether outcomes were measured during or after the session.
Rheumatoid arthritis evidence is thinner and older. Small trials have reported short-term reductions in hand pain during stimulation, but the quality is low and sample sizes are small. For hip osteoarthritis, evidence is sparse enough that conclusions are weak. The honest summary is that TENS has the strongest (though still modest) support in knee osteoarthritis, plausible short-term benefit in hand arthritis, and insufficient evidence elsewhere.
One counterintuitive detail deserves attention. In several well-controlled trials, sham TENS units that delivered no meaningful current performed nearly as well as active units, and in some analyses the difference was not statistically significant. This does not prove TENS is worthless. It suggests that expectation, attention, and the ritual of treatment contribute substantially to reported relief, and that trial design in this field is difficult. A clinician would say the effect is real for some patients but hard to separate from placebo in groups.
When TENS is a reasonable choice and when it is not
TENS fits best as an adjunct for people whose arthritis pain is activity-related and who want to reduce reliance on pain medication. It suits someone who wants to walk further, garden longer, or get through physical therapy with less discomfort. Because it is drug-free and noninvasive, it slots alongside exercise and weight management rather than replacing them. Exercise remains the intervention with the largest and most durable effect on osteoarthritis pain and function.
It fits poorly as a stand-alone strategy. If pain is severe enough to limit sleep or basic mobility, a TENS unit alone will not close the gap. It also fits poorly when the diagnosis is unclear. New joint pain, especially with swelling, warmth, fever, or morning stiffness lasting more than an hour, needs medical evaluation before any device is used, because those features suggest inflammatory or infectious causes that TENS will not address.
Certain situations call for caution or avoidance.
Do not place electrodes over the front or sides of the neck, over the head, or across the chest, because current can affect the heart or airway muscles. Do not use TENS if you have a pacemaker or implanted defibrillator without explicit cardiology approval. Avoid electrodes over broken skin, infected areas, or areas with reduced sensation, such as in diabetic neuropathy. Do not use TENS during pregnancy over the abdomen or pelvis without medical advice. Stop and seek care if stimulation causes skin burns, chest pain, palpitations, or a rash that persists. Do not apply electrodes over an area with a metal implant near the skin surface without checking with your clinician.
These warnings come from device labeling and clinical guidance and are consistent across major regulators. They are not hypothetical: skin burns from improper electrode placement and prolonged high-intensity use are among the most commonly reported TENS injuries.
Comparison with other arthritis pain options
| Option | Typical effect on pain | Onset and duration | Cost (US) | Key limitation |
|---|---|---|---|---|
| TENS | Small-to-moderate, during use | Minutes; fades after session | USD 30 for a basic unit | No effect on joint disease; results vary |
| Exercise therapy | Moderate-to-large, durable | Weeks; persists with adherence | Low to moderate | Requires sustained effort |
| Topical NSAID gel | Small-to-moderate | Hours per application | USD 15 to 40 per tube | Local skin irritation; limited to superficial joints |
| Oral NSAIDs | Moderate | Hours per dose | Low | GI, kidney, and cardiovascular risks with long use |
| Intra-articular corticosteroid injection | Moderate-to-large, short-term | Days; weeks of relief | USD 100 to 300 per injection | Repeated injections have limits |
| Weight loss (if overweight) | Moderate for knee load | Months | Varies | Requires sustained change |
The table makes the trade-off visible. TENS has the lowest risk profile of the drug options and the least durable effect of nearly everything else. For a person who cannot take NSAIDs or wants to reduce their use, that trade-off can be worthwhile. For someone seeking durable pain reduction, exercise and weight management carry more evidence per unit of effort.
The time course of a TENS trial
| Time point | What to expect | What to assess |
|---|---|---|
| Before first use | Baseline pain and function | Record pain during a standard activity, such as a 10-minute walk |
| First 10 to 20 minutes | Tingling; possible early relief | Confirm the sensation is comfortable, not painful |
| End of first session | Peak relief for many users | Rate pain again during the same standard activity |
| 1 to 2 weeks of regular use | Effects become apparent if they will occur | Compare activity tolerance with baseline |
| 4 weeks | Clear signal of benefit or no benefit | Decide whether to continue |
| After stopping | Relief typically fades within hours to days | Note whether benefit carried over at all |
| Beyond 3 months | No disease modification expected | Reassess goals and combine with exercise |
A four-week trial is a reasonable personal test. If pain during a standard activity has not improved by then, more use is unlikely to help. Stopping is not a failure; it is information.
Common misconceptions about TENS and arthritis
The most persistent misconception is that TENS treats arthritis itself. It does not. Electrical current does not reach cartilage, reduce synovitis, or slow joint-space narrowing. Anyone who markets a device as disease-modifying is overselling. The relief, when it comes, is symptomatic and occurs in the nervous system.
A second misconception is that stronger current means better relief. Intensity should produce a comfortable tingling, not muscle contraction or pain. Higher settings raise the risk of skin irritation and burns without evidence of greater benefit. More is not better here.
A third is that TENS replaces medication or exercise. It does neither. Trials comparing TENS with exercise consistently favor exercise for durable outcomes. TENS is best understood as a tool for getting through an activity, not as a treatment program.
A fourth misconception concerns placement. Electrodes belong around the painful joint, not directly on it, and the pattern of placement affects which nerve fibers are recruited. A physical therapist can show correct placement in one visit, which is often more valuable than any instruction manual.
Practical steps to test a TENS unit yourself
Start with a low-cost unit rather than a premium one. Basic devices cost around USD 30 and deliver the same current parameters as models costing several times more. Features like multiple channels and preset programs are conveniences, not efficacy upgrades. Buy from a seller that accepts returns.
Before buying, confirm your situation. If you have a pacemaker, implanted defibrillator, or are pregnant, ask your clinician first. If you have diabetes with reduced foot sensation, avoid using TENS on the feet without supervision.
Set up a fair test. Pick one standard activity, such as walking a set route or climbing stairs, and rate pain from 0 to 10 before and after. Use the device for 20 to 30 minutes before the activity at a comfortable tingling intensity. Repeat for two weeks. Record the ratings.
Reconcile the thresholds explicitly. A reduction of 1 to 2 points on a 0-to-10 scale is the usual threshold for a clinically meaningful individual improvement, and a 10-point change on a 100-point scale is its equivalent. Trial averages in knee osteoarthritis sit near or just below that threshold, which means group data predict modest benefit but individual responses vary widely. Some users report clear relief; many report little.
Decide at four weeks. If your recorded ratings show a consistent improvement of at least 1 to 2 points during the standard activity, the device is earning its place. If not, return it or shelve it. Do not keep using it out of sunk-cost reasoning.
Combine, do not substitute. Continue exercise and weight management, and discuss medication changes with a clinician rather than adjusting them around device use.
Limits of the evidence and of the device
The evidence base for TENS in arthritis has real weaknesses. Trials are often small, blinding is imperfect because users can feel active stimulation, and outcome measures vary, which makes pooling difficult. Reviews that account for these problems tend to find small effects or effects confined to the stimulation period. That is not the same as no effect, but it is far from strong evidence.
The device itself has a ceiling. It cannot alter joint biology, and its relief fades when it stops. It should not delay evaluation of new or worsening joint symptoms, and it should not be used as a reason to avoid exercise or medical care. For most people with arthritis, TENS is a modest comfort tool that works best in combination with the interventions that actually change the course of symptoms. That is a narrower promise than advertising makes, and a more honest one.
For anyone weighing a purchase, the decision reduces to a simple question: is a small, temporary reduction in activity-related pain worth about USD 30 and a few minutes per session? For some people with knee osteoarthritis, the answer is yes. For those seeking durable relief, the evidence points elsewhere.